Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN)
Describe the practice patterns of therapeutic agents for treatment of advanced prostate cancer and overall survival and identify clinical and molecular disease subtypes that predict response to individual treatments, combinations or sequences.
Sample size: 5000
Study scientific committee: Daniel George, Philip Kantoff, Paul Villanti, Lorelei Mucci, Jake Vinson, Stuart Holden
Status: Regulatory process
Sponsor: Prostate Cancer Clinical Trials Consortium, LLC (PCCTC)
55 51 33845334